Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer
December 05, 2015
Denosumab was better at delaying the time to first on-study, skeletal-related event by 18 percent and the time to first and subsequent event by 22 percent. The median time to first on-study, skeletal-related event was five months longer for the denosumab group compared to the zoledronic acid group.
Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2 percent for those taking denosumab and 97.4 percent for those taking zoledronic acid. Jaw osteonecrosis occurred in 2.5 percent of patients taking denosumab and 1.8 percent of those taking zoledronic acid.
Stopeck thinks these results will be practice changing. "We now have an alternative to zoledronic acid that is more convenient, less toxic and more effective for patients with bone metastases," she said.
Source: CTRC-AACR San Antonio Breast Cancer Symposium